5 results
Primary: Longterm safety and tolerability.Secondary: Time to 1st flare, number and severity of flares, efficiacy in treating flares, effect on inflammatory markers, immunogenicity, PK.
Primary objective:To determine whether there is a difference in overall survival (OS) between lurbinectedin (PM01183)/doxorubicin (DOX) and a control armconsisting of best Investigator's choice between cyclophosphamide (CTX), doxorubicin (DOX)…
Primary:To determine the safety, tolerability, MTD (maximum tolerated dose) or the MAD (maximum administered dose) of GSK3359609 in combination with pembrolizumab or chemotherapy with(out) pembrolizumab. Secondary:To determine the recommended dose…
Primary: • Compare the efficacy of GSK3359609 in combination with pembrolizumab to pembrolizumab plus placebo in the PD-L1 expression positive (CPS >=1) population and in the PD-L1 expression high (CPS>=20) populationSecondary: •…
Primary:To determine whether experimental regimens provide evidence for improved survival (randomization to death) over standard of care (SoC) therapy in NSCLC patients.Secondary:Milestone survival, measures of antitumor activity, safety and…